KPT-350 Treatment Improves Histological Hallmarks of Dystrophic Pathology
(A) WT and D2-mdx mice were given oral KPT-350 at 5 mg/kg three times a week for 8 weeks beginning at 8 weeks of age. (B) Tibialis anterior muscles were sectioned and stained in H&E (representative images shown, original magnification ×20, scale bars: 100 μm). KPT-350 treatment significantly increased the frequency of large-size fibers with a concomitant decrease in small-size fibers in both WT and D2-mdx cohorts (C). In addition, KPT-350-treated D2-mdx mice had significantly fewer centralized myonuclei (D) and less inflammation (E) than the vehicle-treated D2-mdx mice. Mean ± SEM. n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA.